Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  erismodegib
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Erismodegib before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1130, NCI-2012-00064, CIR00003888, LDE225XUS03T, NA_00047491, NA_00047491 / CIR00004443, NCT01431794
Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: F140214007 (UAB 1357), NCI-2015-00264, 000505867, NCT02195973
Erismodegib and Lenalidomide after Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC128B, NCI-2014-00170, NCT02086552
Erismodegib, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-206, NCI-2012-00568, NCT01579929
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLDE225A2112, NCI-2013-00557, NCT01769768
Azacitidine and Erismodegib in Treating Patients with Myeloid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1389, NCI-2014-00866, Mod13-009003-08, NCT02129101
Erismodegib and Everolimus in Treating Patients with Advanced Gastroesophageal Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0838, NCI-2014-01455, NCT02138929
Erismodegib in Treating Patients with Advanced or Metastatic Liver Cancer That Cannot Be Removed by Surgery or Child-Pugh A Cirrhosis
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDE225XUS12T, NCI-2014-01762, 131053, HRPP #131053, NCT02151864
Erismodegib in Treating Patients with Refractory Chronic Graft-versus-Host Disease after Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 13-598, NCI-2015-00622, LDE225XUS16T, NCT02086513
Erismodegib in Treating Patients With Locally Advanced or Metastatic Basal Cell Skin Cancer Who Previously Received Smo Inhibitor Treatment
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0009, NCI-2012-00042, 21759, NCT01529450
Erismodegib in Treating Patients with High-Risk Localized Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1402, NCI-2014-02144, LDE225XUS13T, NA_00091602, NCT02111187
Start Over